Compare Marsh & McLennan Companies, Inc. (MRSH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Neurocrine Biosciences Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $188.85 (market cap $90.13B), while Neurocrine Biosciences Inc trades at $150 (market cap $15.91B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 5.7× Neurocrine Biosciences Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.1% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MRSH | NBIX | |
|---|---|---|
Market Cap | $90.13B | $15.91B |
Sector | Financials | Health |
52-Week High | $211.21 | $185.50 |
52-Week Low | $157.32 | $123.10 |
Enterprise Value | $110.81B | $15.92B |
Dividend Yield | 2.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $188.69, down 1.34% on the day, with a bullish technical signal supported by moving averages and an oversold RSI. The company reported strong Q2 2026 earnings, beating estimates with $2.96 EPS, and maintains solid fundamentals including a 14.24% net income margin and 25.72% ROE. Recent acquisitions, such as MMA's deal for Accel, highlight strategic growth initiatives.
The outlook remains positive with a consensus price target of $202.89, though risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity shows mixed positions, with Bank of America reducing holdings while others like Ashton Thomas Securities added new stakes, reflecting cautious optimism.
Neurocrine Biosciences (NBIX) trades at $156.49, down 3.37% amid recent safety concerns over Vykat XR. The stock shows strong fundamentals with a P/E of 22.88, net income margin of 20.91%, and robust revenue growth. Technical indicators are bearish, with price near support at $155. Recent Q2 2026 earnings beat estimates, but Q3 expectations are high at $2.59 EPS.
Outlook remains positive due to strong analyst consensus (86.49% buy) and a $208.82 price target, though risks include drug safety issues and competitive pressures. Earnings growth and pipeline advancements offer upside, but volatility from news flow requires careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
